Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Chiesi Farmaceutici S.p.A. |
---|---|
Information provided by: | Chiesi Farmaceutici S.p.A. |
ClinicalTrials.gov Identifier: | NCT00868023 |
Multinational, multicentre, randomised, double blind, double dummy, placebo and active controlled, 5-way cross over
Condition | Intervention | Phase |
---|---|---|
Asthma |
Drug: CHF 1535 Next DPI Drug: Foster BDP/Formoterol Drug: Placebo |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Investigator), Active Control, Crossover Assignment, Safety/Efficacy Study |
Official Title: | A Phase II, Multinational, Multicentre, Double Blind, Double Dummy, Randomised, 5-Way Cross-Over, Placebo and Active Controlled Clinical Study to Test the Non-Inferiority of a Single Dose of CHF 1535 (Fixed Combination of Beclomethasone Dipropionate 100 µg Plus Formoterol Fumarate 6 µg Dry Powder) Via NEXT™ DPI 1 or 4 Inhalations Versus CHF 1535 (Beclomethasone Dipropionate 100 µg Plus Formoterol Fumarate 6 µg) pMDI With HFA-134a Propellant 1 or 4 Puffs on FEV1 AUC0-12h in Partly Controlled Adult Asthmatic Patients |
Estimated Enrollment: | 95 |
Study Start Date: | February 2009 |
Estimated Study Completion Date: | October 2009 |
Estimated Primary Completion Date: | September 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental
CHF 1535 DPI : BDP/Formo 400/24 µg
|
Drug: CHF 1535 Next DPI
CHF 1535 DPI : BDP/Formoterol : 100/6 µg (daily dose : BDP/Formoterol : 400/24 µg)
|
2: Active Comparator
CHF 1535 pMDI HFA : BDP/Formo 400/24 µg
|
Drug: Foster BDP/Formoterol
BDP/Formoterol 100/6 µg (daily dose : BDP/Formoterol : 400/24 µg)
|
3: Experimental
CHF 1535 DPI : BDP/Formo 100/6 µg
|
Drug: CHF 1535 Next DPI
CHF 1535 DPI : BDP/Formoterol : 100/6 µg (daily dose : BDP/Formoterol : 100/6 µg)
|
4: Active Comparator
CHF 1535 pMDI HFA : BDP/Formo 100/6 µg
|
Drug: Foster BDP/Formoterol
BDP/Formoterol 100/6 µg (daily dose : BDP/Formoterol : 100/6 µg
|
5: Placebo Comparator
Placebo
|
Drug: Placebo
Placebo
|
To demonstrate the non-inferiority in terms of FEV1 AUC0-12h between a single dose of CHF 1535 via NEXT DPI and CHF 1535 via HFA-134a "extrafine" pMDI in partly controlled adult asthmatic patients
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Martine Cartier | +33147684358 | m.cartier@chiesifrance.com |
United Kingdom | |
Pr DS SINGH | Recruiting |
Manchester, United Kingdom, M23 9QZ |
Principal Investigator: | David Singh, Professor | Medecines Evaluation Unit - Southmoor Road - M23 9QZ Manchester - UK |
Responsible Party: | Medecines Evaluation Unit - Southmoor Road - M23 9QZ Manchester - United Kingdom ( Pr SD Singh ) |
Study ID Numbers: | CCD-0809-PR-0038 |
Study First Received: | March 23, 2009 |
Last Updated: | March 23, 2009 |
ClinicalTrials.gov Identifier: | NCT00868023 History of Changes |
Health Authority: | France: Afssaps - French Health Products Safety Agency; Italy: Ethics Committee; United Kingdom: Medicines and Healthcare Products Regulatory Agency |
Anti-Inflammatory Agents Neurotransmitter Agents Adrenergic Agents Adrenergic beta-Agonists Hormone Antagonists Hormones, Hormone Substitutes, and Hormone Antagonists Asthma Beclomethasone |
Anti-Asthmatic Agents Glucocorticoids Hormones Adrenergic Agonists Formoterol Peripheral Nervous System Agents Bronchodilator Agents |
Anti-Inflammatory Agents Respiratory System Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Adrenergic Agents Adrenergic beta-Agonists Physiological Effects of Drugs Hormones, Hormone Substitutes, and Hormone Antagonists Beclomethasone Anti-Asthmatic Agents |
Glucocorticoids Hormones Pharmacologic Actions Adrenergic Agonists Autonomic Agents Therapeutic Uses Formoterol Peripheral Nervous System Agents Bronchodilator Agents |